GO:0061156 pulmonary artery morphogenesis: Developmental Process, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0061156 pulmonary artery morphogenesis describes the biological process by which the anatomical structures of the pulmonary artery are generated and organized during development.
• Transcription factors such as FOXM1 and RUNX2 regulate key steps in pulmonary vascular development and remodeling.
• Disruption of pulmonary artery morphogenesis contributes to congenital heart defects, pulmonary arterial hypertension, and pulmonary stenosis.
• Prenatal echocardiography and Doppler ultrasound are critical tools for assessing pulmonary artery development and detecting outflow tract obstruction.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of genes involved in pulmonary artery morphogenesis.
• Understanding this process informs therapeutic strategies for pulmonary vascular diseases and congenital heart malformations.
Description
Pulmonary artery morphogenesis (GO:0061156) is the developmental process responsible for generating and organizing the anatomical structures of the pulmonary artery, the vessel that carries blood from the heart to the lungs. This process is essential for establishing a functional pulmonary circulation at birth and for maintaining normal cardiovascular physiology throughout life. Defects in pulmonary artery morphogenesis are associated with congenital heart disease, pulmonary stenosis, and pulmonary arterial hypertension. Research into this process has been advanced by studies of transcription factors that regulate embryonic development of the pulmonary vasculature, as well as by investigations into the molecular mechanisms driving pathological vascular remodeling. Understanding the genes and signaling pathways that control pulmonary artery morphogenesis is critical for developing diagnostic and therapeutic strategies for pulmonary vascular disorders.
pulmonary artery morphogenesis At A Glance
| GO ID | GO:0061156 |
|---|---|
| GO term | pulmonary artery morphogenesis |
| Ontology | biological_process |
| Synonym | None |
| Major function | Generation and organization of pulmonary artery anatomical structures |
| Related processes | Embryonic development of pulmonary vasculature, vascular remodeling |
| Key regulators | Transcription factors including FOXM1 and RUNX2 |
| Clinical relevance | Congenital heart defects, pulmonary stenosis, pulmonary arterial hypertension |
What Is GO:0061156?
GO:0061156 pulmonary artery morphogenesis is defined as the process in which the anatomical structures of the pulmonary artery are generated and organized. The pulmonary artery is the artery that carries blood from the heart to the lungs. This biological process encompasses the coordinated cellular and molecular events that shape the pulmonary artery during embryonic and fetal development, ensuring proper connection between the right ventricle and the pulmonary circulation.
Why Is pulmonary artery morphogenesis Important in Cell Biology?
Pulmonary artery morphogenesis is fundamental to cardiovascular development because it establishes the conduit for blood oxygenation after birth. Disruptions in this process lead to congenital anomalies such as pulmonary stenosis and contribute to the pathogenesis of pulmonary arterial hypertension, a progressive and often fatal disease. Studying the molecular regulators of pulmonary artery morphogenesis provides insight into normal vascular development and identifies potential therapeutic targets for pulmonary vascular diseases.
• Essential for establishing functional pulmonary circulation at birth.
• Defects cause congenital heart defects including pulmonary stenosis.
• Dysregulation contributes to pulmonary arterial hypertension.
• Transcription factors like FOXM1 drive pulmonary artery smooth muscle cell expansion in disease.
• RUNX2 stabilization by TAZ promotes pulmonary artery calcification and remodeling.
• Prenatal Doppler ultrasound can assess fetal pulmonary artery pressure and flow.
• Pulmonary outflow tract obstruction alters pulmonary artery blood flow patterns in fetuses.
• Animal models and CRISPR screens enable functional dissection of morphogenetic pathways.
• Informs development of therapies targeting vascular remodeling.
• Provides biomarkers for prenatal diagnosis of pulmonary stenosis.
What Happens During pulmonary artery morphogenesis?
Specification of Pulmonary Vascular Progenitors
In simple terms: Early in development, certain cells are told to become part of the future pulmonary artery.
During embryogenesis, progenitor cells in the splanchnic mesoderm and neural crest are specified to form the pulmonary vascular system. Transcription factors regulate the early patterning of the pulmonary artery, ensuring that it connects properly to the right ventricle and the lung vasculature. Disruptions in these early specification events can lead to congenital anomalies such as pulmonary atresia or stenosis.
Vasculogenesis and Angiogenesis
In simple terms: New blood vessels are formed and then sprout to build the pulmonary artery network.
Vasculogenesis creates the initial vascular tubes, while angiogenesis extends and remodels them into a hierarchical network. In the developing lung, pulmonary artery smooth muscle cells proliferate and migrate to invest the endothelial tubes, a process regulated by transcription factors such as FOXM1. Proper coordination of these events is essential for normal pulmonary artery morphogenesis.
Remodeling and Maturation
In simple terms: The pulmonary artery changes its structure to become a mature, functional blood vessel.
After the initial vascular network is established, the pulmonary artery undergoes remodeling to acquire its final architecture, including the formation of distinct layers (intima, media, adventitia). This maturation involves changes in extracellular matrix composition and smooth muscle cell phenotype. In pathological conditions, aberrant remodeling can lead to pulmonary arterial hypertension, where RUNX2 stabilization by TAZ drives calcification and vascular remodeling.
Integration with Cardiac Outflow Tract
In simple terms: The pulmonary artery must connect correctly to the heart's right ventricle.
Proper alignment and connection of the pulmonary artery with the right ventricular outflow tract are critical for normal circulation. Defects in this integration result in conotruncal anomalies. Studies using fetal echocardiography have shown that pulmonary outflow tract obstruction alters pulmonary artery blood flow patterns, which can be detected prenatally. The morphogenesis of coronary arteries in congenitally malformed hearts also highlights the importance of coordinated outflow tract development.
Functional Adaptation at Birth
In simple terms: At birth, the pulmonary artery must adapt to carry full blood flow to the lungs.
At birth, pulmonary vascular resistance drops dramatically, and the pulmonary artery must accommodate increased blood flow. This functional adaptation involves vasodilation and structural changes. Prenatal Doppler evaluation of fetal pulmonary artery pressure provides insights into the hemodynamic environment that prepares the pulmonary artery for postnatal function.
Key Genes Involved in GO:0061156 pulmonary artery morphogenesis
The following genes and proteins have been implicated in the regulation of pulmonary artery morphogenesis and related vascular remodeling processes.
| Gene | Major Role | Research Relevance |
|---|---|---|
| FOXM1 | Promotes pulmonary artery smooth muscle cell expansion | Implicated in pulmonary arterial hypertension |
| RUNX2 | Drives pulmonary artery calcification and remodeling | Stabilized by TAZ in pulmonary hypertension |
| TAZ | Stabilizes RUNX2 | Contributes to vascular remodeling in left heart disease |
| NOTCH | Regulates vascular development | Involved in pulmonary artery morphogenesis |
| VEGF | Promotes angiogenesis | Essential for pulmonary vascular development |
| BMPR2 | Regulates smooth muscle proliferation | Mutated in heritable pulmonary arterial hypertension |
| TGF-beta | Signaling in vascular remodeling | Key pathway in pulmonary artery morphogenesis |
| Sox17 | Endothelial transcription factor | Regulates pulmonary vascular development |
| Hey2 | Notch target gene | Involved in arterial specification |
| COUP-TFII | Regulates vascular patterning | Implicated in pulmonary artery development |
| Pitx2 | Left-right asymmetry | Affects pulmonary artery patterning |
| Tbx1 | Outflow tract development | Associated with conotruncal defects |
| GATA6 | Smooth muscle differentiation | Regulates pulmonary vascular remodeling |
| ELN | Elastin production | Critical for arterial wall integrity |
| FBN1 | Extracellular matrix protein | Mutations affect vascular development |
| ACVRL1 | TGF-beta receptor | Mutated in hereditary hemorrhagic telangiectasia |
| ENG | TGF-beta co-receptor | Associated with vascular malformations |
How Is pulmonary artery morphogenesis Regulated?
Pulmonary artery morphogenesis is regulated by a complex network of transcription factors, growth factors, and signaling pathways. Key regulators include FOXM1, which promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension, and RUNX2, which is stabilized by TAZ and drives pulmonary artery calcification and remodeling. Additional transcription factors controlling embryonic development of the pulmonary vasculature have been reviewed. Hemodynamic forces, such as blood flow and pressure, also influence pulmonary artery development, as assessed by fetal Doppler studies. Disruption of these regulatory mechanisms can lead to congenital or acquired pulmonary vascular diseases.
pulmonary artery morphogenesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| FOXM1 | Pulmonary arterial hypertension | Knockout mouse, siRNA in PASMC |
| RUNX2 | Pulmonary artery calcification | Overexpression in vascular smooth muscle cells |
| TAZ | Vascular remodeling in left heart disease | Knockdown in pulmonary artery smooth muscle cells |
| BMPR2 | Heritable pulmonary arterial hypertension | Knockout rat, CRISPR knock-in |
| NOTCH | Congenital heart defects | Zebrafish knockout |
Pulmonary Arterial Hypertension
Pulmonary arterial hypertension (PAH) is characterized by excessive proliferation and remodeling of pulmonary artery smooth muscle cells, leading to increased vascular resistance and right heart failure. FOXM1 has been shown to promote pulmonary artery smooth muscle cell expansion in PAH. Additionally, RUNX2 stabilization by TAZ drives pulmonary artery calcification and lung vascular remodeling in pulmonary hypertension due to left heart disease. These findings link dysregulated pulmonary artery morphogenesis pathways to disease pathogenesis.
Congenital Pulmonary Stenosis
Pulmonary stenosis is a congenital heart defect characterized by narrowing of the pulmonary valve or artery. Prenatal echocardiography can predict postnatal pulmonary stenosis by assessing pulmonary artery flow patterns and valve morphology. Fetuses with pulmonary outflow tract obstruction exhibit altered pulmonary artery blood flow patterns, which can be detected by Doppler ultrasound. These observations highlight the clinical importance of understanding normal pulmonary artery morphogenesis.
Coronary Artery Anomalies in Congenitally Malformed Hearts
Abnormal coronary artery morphogenesis often accompanies congenital heart defects, including those affecting the pulmonary outflow tract. The morphogenesis of abnormal coronary arteries in congenitally malformed hearts has been studied to understand the developmental relationship between coronary and pulmonary vascular systems. This suggests shared developmental mechanisms between pulmonary artery and coronary artery morphogenesis.
From pulmonary artery morphogenesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does FOXM1 drive PASMC expansion in PAH? | FOXM1 knockout or knockdown in rodent PAH models |
| Does RUNX2 stabilization cause pulmonary artery calcification? | RUNX2 overexpression or TAZ knockdown in vascular smooth muscle cells |
| What is the role of BMPR2 in pulmonary artery morphogenesis? | BMPR2 knockout rat or CRISPR knock-in |
| How does altered blood flow affect pulmonary artery development? | Fetal Doppler ultrasound in animal models |
| Can prenatal echocardiography predict pulmonary stenosis? | Human fetal echocardiography cohort |
| What transcription factors regulate pulmonary vascular development? | Conditional knockout mice for candidate genes |
How to Study the pulmonary artery morphogenesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Prenatal echocardiography | Pulmonary artery flow and valve morphology | Diagnosis of pulmonary stenosis |
| Doppler ultrasound | Fetal pulmonary artery pressure and flow patterns | Assessment of outflow tract obstruction |
| Conditional knockout mice | Gene function in pulmonary artery development | Dissecting developmental pathways |
| siRNA knockdown | Protein depletion in PASMCs | Studying FOXM1 in PAH |
| Co-immunoprecipitation | Protein-protein interactions | TAZ-RUNX2 stabilization |
| Immunohistochemistry | Protein localization in tissue sections | Assessing vascular remodeling |
| RNA-seq | Transcriptomic changes | Identifying regulators of morphogenesis |
| CRISPR screen | Gene function in vascular development | High-throughput discovery |
Prenatal Echocardiography and Doppler
Prenatal echocardiography and Doppler ultrasound are non-invasive methods to assess fetal pulmonary artery development and hemodynamics. These techniques can measure pulmonary artery pressure, flow patterns, and valve morphology, aiding in the diagnosis of pulmonary stenosis and outflow tract obstruction. Predictive models using prenatal echocardiography have been developed to diagnose postnatal pulmonary stenosis.
Genetic Lineage Tracing and Knockout Models
Conditional knockout and lineage tracing in mice are powerful approaches to study the role of specific genes in pulmonary artery morphogenesis. For example, knockout of transcription factors such as FOXM1 or BMPR2 can reveal their contributions to pulmonary vascular development and disease. These models allow researchers to dissect cell-autonomous and non-cell-autonomous functions.
Molecular and Cellular Assays
In vitro assays using pulmonary artery smooth muscle cells (PASMCs) and endothelial cells are used to study proliferation, migration, and differentiation. FOXM1 expression and activity can be modulated by siRNA or overexpression to assess effects on PASMC expansion. RUNX2 stabilization by TAZ can be studied using co-immunoprecipitation and ubiquitination assays.
Imaging and Histology
Histological analysis of pulmonary artery sections, including immunohistochemistry for smooth muscle actin and elastin, provides structural information. Advanced imaging such as micro-CT and optical coherence tomography can visualize pulmonary artery architecture in animal models. These methods complement functional studies to understand morphogenetic defects.
How CRISPR Can Be Used to Study GO:0061156 pulmonary artery morphogenesis
Knockout
CRISPR knockout of candidate genes such as FOXM1 or BMPR2 in pulmonary artery smooth muscle cells or animal models can determine their necessity for pulmonary artery morphogenesis. For example, FOXM1 knockout reduces PASMC expansion, implicating it in PAH. Knockout of transcription factors regulating embryonic pulmonary vasculature can reveal developmental defects.
Point Mutation
CRISPR point mutation can model specific genetic variants associated with pulmonary artery diseases, such as mutations in BMPR2 or ACVRL1. These models help understand how single amino acid changes affect protein function and contribute to disease phenotypes.
Knock-in
Knock-in of reporter genes or epitope tags allows visualization and tracking of specific proteins during pulmonary artery morphogenesis. For example, tagging RUNX2 with a fluorescent protein enables live imaging of its localization and stabilization by TAZ. Knock-in of disease-associated mutations can create accurate disease models.
Overexpression
CRISPR activation (CRISPRa) or transgenic overexpression can elevate expression of genes such as RUNX2 or TAZ to study their sufficiency in driving pulmonary artery remodeling. Overexpression of RUNX2 in vascular smooth muscle cells induces calcification, mimicking aspects of pulmonary hypertension.
How EDITGENE Supports pulmonary artery morphogenesis Research
Researchers studying pulmonary artery morphogenesis-related genes often need to determine whether a candidate gene is causally involved in vascular development or disease. EDITGENE provides comprehensive CRISPR-based services to enable precise genetic manipulation in relevant cell models and animal models, accelerating functional discovery.
Contact EDITGENE today to design your custom CRISPR model for pulmonary artery morphogenesis research.
Frequently Asked Questions About pulmonary artery morphogenesis
What is pulmonary artery morphogenesis?
Pulmonary artery morphogenesis (GO:0061156) is the biological process by which the anatomical structures of the pulmonary artery are generated and organized during development.
What genes are involved in pulmonary artery morphogenesis?
Key genes include FOXM1, RUNX2, TAZ, BMPR2, NOTCH, and various transcription factors regulating embryonic pulmonary vasculature.
How is pulmonary artery morphogenesis studied?
It is studied using prenatal echocardiography, Doppler ultrasound, genetic knockout models, and molecular assays in pulmonary artery smooth muscle cells.
What diseases are associated with defective pulmonary artery morphogenesis?
Defects are linked to pulmonary stenosis, pulmonary arterial hypertension, and congenital heart defects.
What is the role of FOXM1 in pulmonary artery morphogenesis?
FOXM1 promotes pulmonary artery smooth muscle cell expansion and is implicated in pulmonary arterial hypertension.
How does RUNX2 affect pulmonary artery morphogenesis?
RUNX2, stabilized by TAZ, drives pulmonary artery calcification and vascular remodeling in pulmonary hypertension.
Can CRISPR be used to study pulmonary artery morphogenesis?
Yes, CRISPR knockout, knock-in, and overexpression models enable functional studies of genes involved in pulmonary artery development and disease.
What is the clinical significance of pulmonary artery morphogenesis?
Understanding it helps diagnose and treat congenital heart defects and pulmonary vascular diseases.
What methods assess fetal pulmonary artery development?
Prenatal echocardiography and Doppler ultrasound assess pulmonary artery flow, pressure, and valve morphology.
What transcription factors regulate pulmonary vascular development?
Transcription factors such as FOXM1, RUNX2, and others reviewed in the literature control embryonic development of the pulmonary vasculature.
Conclusion
Pulmonary artery morphogenesis (GO:0061156) is a critical developmental process that ensures proper formation of the pulmonary artery. Dysregulation of this process contributes to congenital heart defects and pulmonary vascular diseases such as pulmonary arterial hypertension. Research using genetic models, imaging, and molecular assays continues to uncover the genes and pathways involved. EDITGENE provides essential CRISPR tools to accelerate this research and facilitate the development of targeted therapies.
References
- 1. Liu SF et al.. 2024. RUNX2 is stabilised by TAZ and drives pulmonary artery calcification and lung vascular remodelling in pulmonary hypertension due to left heart disease.. Eur Respir J 64(5) PMID: 39542509
- 2. Wang L et al.. 2026. The Predictive Role of Prenatal Echocardiography in the Diagnosis of Postnatal Pulmonary Stenosis.. Pediatr Cardiol 47(4):1750-1757 PMID: 40736580
- 3. Sosa-Olavarria A et al.. 2019. Doppler evaluation of the fetal pulmonary artery pressure.. J Perinat Med 47(2):218-221 PMID: 30433877
- 4. Bourgeois A et al.. 2018. FOXM1 promotes pulmonary artery smooth muscle cell expansion in pulmonary arterial hypertension.. J Mol Med (Berl) 96(2):223-235 PMID: 29290032
- 5. Brezinka C. 2001. Fetal hemodynamics.. J Perinat Med 29(5):371-80 PMID: 11723838
- 6. Peyvandi S et al.. 2014. Pulmonary artery blood flow patterns in fetuses with pulmonary outflow tract obstruction.. Ultrasound Obstet Gynecol 43(3):297-302 PMID: 23554091
- 7. Anderson RH et al.. 2022. The morphogenesis of abnormal coronary arteries in the congenitally malformed heart.. J Thorac Cardiovasc Surg 164(2):344-349 PMID: 34666912
- 8. Bolte C et al.. 2018. Transcription Factors Regulating Embryonic Development of Pulmonary Vasculature.. Adv Anat Embryol Cell Biol 228:1-20 PMID: 29288383
